Uterine Fibroid Treatment Drugs Market Is Expected To Reach $ 3.91 Billion By 2030


 San Francisco, 17 Aug 2023: The Report Uterine Fibroid Treatment Drugs Market Size, Share & Trends Analysis Report By Drug Class (GnRH Agonists, GnRH Antagonists), By Type (Submucosal Fibroids, Intramural Fibroids), By End-user, And Segment Forecasts, 2023 - 2030

The global uterine fibroid treatment drugs market size is expected to reach USD 3.91 billion by 2030, expanding at a CAGR of 10.2% from 2022 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is attributed to the rising prevalence of Uterine Fibroids (UF) and the increased effectiveness of novel drugs in reducing heavy menstrual bleeding in women. According to an article published on IntechOpen, heavy menstrual bleeding is a common symptom of uterine fibroids affecting approximately 1.4 million women per year. In addition, nearly 60% of women report that symptoms impede physical activity and affect their quality of life. Moreover, 24% of women reported that symptoms prevent them from performing to their full ability at work.

Therefore, the rising demand for novel drugs with an advanced mechanism of action, higher clinical efficacy & lesser side effects is expected to drive the market. In addition, rising funding for research activities is expected to boost market growth. For instance, the Society for Women’s Health Research (SWHR) endorsed the updated & re-introduced Stephanie Tubbs Jones Uterine Fibroid Research & Education Act of 2021. The act is designed to advance funding for research and enhance education regarding the condition. The recent approval of multiple Gonadotropin-releasing Hormone (GnRH) antagonists for the treatment of heavy bleeding associated with fibroids will also drive the market. For instance, in May 2020, the U.S. FDA approved Oriahnn for the treatment of uterine fibroids.

It became the first oral medication approved for the treatment of heavy bleeding in pre-menopausal women. The drug has a treatment duration of 24 months and is available at a retail price of USD 1,100 for 56 tablets. Furthermore, key players are focusing on new launches, mergers & acquisitions, expansion, and partnerships for gaining higher market shares. For instance, in June 2022, Kissei Pharmaceuticals announced the initiation of Phase III trials for its drug, linzagolix, for the treatment of uterine fibroids, in Japan. The drug has already been approved by EMA under the brand name Yselty in Europe. The original developer, ObsEva, sold the regional rights for this drug to Theramex in Feb 2022. The deal grants Theramex the rights to sell this drug in Europe, Brazil, and Australia.

Access Research Report of Uterine Fibroid Treatment Drugs Market @ https://www.grandviewresearch.com/industry-analysis/uterine-fibroid-treatment-drugs-market-report

Uterine Fibroid Treatment Drugs Market Report Highlights

  • The GnRH antagonists segment is expected to register the fastest growth rate over the forecast period
  • The recent approval of multiple drugs, such as Oriahnn in May 2020 in the U.S., Myfembree in May 2021 in the U.S., and Yselty in June 2022 in Europe, is expected to drive market growth
  • The submucosal fibroids segment held the majority of the share of the UF drugs market in 2022
  • Retail pharmacies dominated the market in 2022 on account of the ease of availability of medications in these pharmacies
  • North America held the largest share of the global market in 2022 due to various factors, such as the presence of major players, the high prevalence of the health condition, and increasing awareness among patients regarding the availability of medications

Uterine Fibroid Treatment Drugs Market Report Scope

Report Attribute

Details

Market size value in 2023

USD 2.0 billion

Revenue forecast in 2030

USD 3.91 billion

Growth rate

CAGR of 10.2% from 2023 to 2030

Base year for estimation

2022

Historical data

2018 - 2021

Forecast period

2023 - 2030

List of Key Players in Uterine Fibroid Treatment Drugs Market

  • Myovant Sciences GmbH
  • Pfizer Inc.
  • Abbvie, Inc.
  • Ferring B.V.
  • AstraZeneca
  • Bayer AG
  • Amring Pharmaceuticals Inc.
  • Watson Pharma, Inc.

Access Press Release of Uterine Fibroid Treatment Drugs Market @ https://www.grandviewresearch.com/press-release/global-uterine-fibroid-treatment-drugs-market

 

Comments

Post a Comment

Popular posts from this blog

Asia Pacific PoC Diagnostics Market Growth Opportunities, Industry Analysis And Forecast: Grand View Research Inc.

Image
San Francisco, 18 March 2020 :  The Report   Asia Pacific PoC Diagnostics Market  Analysis And Segment Forecasts To 2020 The Asia Pacific point of care (PoC) diagnostics market is expected to reach USD 5,427.1 million by 2020, according to a new study by Grand View Research, Inc. Growing base of geriatric population and the ability to render immediate results and improve patient care coupled with rising market penetration of PACS (picture archiving and communication systems) and EMR (electronic medical records) are expected to drive demand over the next six years. Skilled staff shortages, especially pertaining to the field of diagnostics are also expected to accelerate the market penetration rates of PoC products, by expediting lab automation processes. Rising demand for home healthcare and other healthcare establishments catering to the elderly population and initiatives undertaken by governments to shorten hospital stays by establishing out-patient care models are also expect
Read more

Food Additives Market Size & Share Hit USD 55.53 Billion By 2022 : Grand View Research Inc.

Image
San Francisco, 17 October 2019:   The Report   Global Food Additives Market   Analysis By Product Flavors & Enhancers (Natural, Artificial), Sweeteners (High Intensity, HFCS), Enzymes, Emulsifiers (Mono, Di-Glycerides, Lecithin, Stearoyl Lactylates, Sorbitan Esters), Shelf-life Stabilizers, Fat Replacers (Protein, Starch)] And Segment Forecast To 2022 Global food additives market is expected to reach USD 55.53 billion by 2022, according to a new study by Grand View Research, Inc. Food & beverage industry growth in BRICS and Middle East on account of rising domestic consumption and increasing foreign direct investments is expected to augment market growth. Asia Pacific is expected to be one of the most promising markets on account of growing domestic consumption in China and India owing to population growth and new product launches by food & beverage manufacturers. Availability of raw materials such as sorbitol and lactic acid in China, Indonesia, and Malaysia in light o
Read more

Integration Platform as a Service Market Valuation Is Expected To Exceed USD 2.70 Billion By 2025: Grand View Research Inc.

Image
San Francisco, 18 March 2020 :  The Report   Integration Platform as a Service (IPaaS) Market  Analysis By Integration Type (API, Process, Application, Data), By Services, By Deployment (Cloud, On-Premise, Hybrid) By Region, And Segment Forecasts, 2018 – 2025 The global integration platform as a service (IPaaS) market is expected to reach USD 2.705.8 million by 2025, according to a new report by Grand View Research, Inc. Rising need of advanced systems to improve the process of deploying, developing, and managing enterprise applications globally has been a major factor driving market growth. In addition, recent developments in big data, cloud computing, and Internet of Things (IoT) within organizations’ processes also paved the way for greater development of IPaaS solutions. Integration Platform as a Service is an emerging technology where in the applications, process, data, and application programs are integrated. The integration enables enterprises to reduce the complexity
Read more